Artivion, Inc. ( AORT ) Nowojorska Giełda Papierów Wartościowych

Cena: 31.41 ( 1.16% )

Aktualizacja 07-25 21:59
Nowojorska Giełda Papierów Wartościowych
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Artivion Inc. Produkuje, procesów i dystrybuuje urządzenia medyczne i wszczepialne ludzkie tkanki na całym świecie. Firma oferuje bioglue, polimer składający się z bydlęcej białka krwi i środka do sieciowego białek do procedur serca, naczyniowych, neurologicznych i płuc; usługi ochrony serca; Photofix, bydlęca łatka osierdziowa; oraz E-VITA Open Plus i E-Vita Open Neo. Zapewnia również systemy inżynierii projektowej E-XTRA do leczenia chorób naczyń aorty; E-SIDE, przeszczep stentu z półki do leczenia choroby piersi-jadalni; E-vita klatki piersiowej 3G do leczenia wewnątrznaczyniowego tętniaków aorty piersiowej; E-NYA, system przeszczepu stentu klatki piersiowej do minimalnie inwazyjnej naprawy zmian zstępującej aorty; E-Ventus BX, przeszczep stentu obwodowego narażonego na balon do leczenia wewnątrznaczyniowego tętnic nerkowych i miednicy; E-liak w leczeniu tętnicy tętniczej biodrowej i tętniak gałęzi boków biodrowych; i E-Tegra, system tętniaków aorty brzusznej stent. Ponadto firma oferuje syntetyczne przeszczepy naczyniowe do stosowania w otwartej aordzie i naczyniowej zabiegu chirurgicznym; Perklot, wchłaniany sproszkowany hemostat do stosowania w zabiegach chirurgicznych; Produkty terapii laserowej sercowej do leczenia dusznicy bolesnej; Cryovein żyła kości udowej i krioarterii tętnicy kości udowej naczyń naczyń; On-X protetyczne zawory aorty i mitralnej oraz rosnąca proteza aorty; Cewki dyfuzyjne CABLAID CO2 i szwy akord-x EPTFE do mitralnej wymiany akordowej; oraz Ascirus Medical Ditection Stent, a także usługi pirolitycznej powlekania węglowego dla producentów urządzeń medycznych. Służy lekarzom, szpitalom i innym placówkach opieki zdrowotnej, a także chirurgów sercowych, naczyniowych, piersiowych i ogólnych. Firma była wcześniej znana jako Cryolife, Inc. i zmieniła nazwę na Artivion Inc. w styczniu 2022 r. Firma została założona w 1984 roku i ma siedzibę w Kennesaw w stanie Georgia.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 1 500
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 94.8223
Ilość akcji: Brak danych
Debiut giełdowy: 1993-02-12
WWW: https://artivion.com
CEO: Mr. James Patrick Mackin
Adres: 1655 Roberts Boulevard N.W.
Siedziba: 30144 Kennesaw
ISIN: US2289031005
Wskaźniki finansowe
Kapitalizacja (USD) 1 341 294 948
Aktywa: 803 144 000
Cena: 31.41
Wskaźnik Altman Z-Score: 2.2
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: -61.6
Ilość akcji w obrocie: 95%
Średni wolumen: 395 777
Ilość akcji 42 702 800
Wskaźniki finansowe
Przychody TTM 384 899 000
Zobowiązania: 498 405 000
Przedział 52 tyg.: 21.97 - 32.94
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -0.5
P/E branży: Brak danych
Beta: 1.749
Raport okresowy: 2025-08-07
WWW: https://artivion.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Jean F. Holloway Esq. Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary 841 430 1957
Mr. John E. Davis Senior Vice President & Chief Commercial Officer 802 017 1965
Ms. Amy D. Horton CPA Vice President & Chief Accounting Officer 621 265 1970
Dr. Marshall S. Stanton M.D. Senior Vice President of Clinical Research & Chief Medical Officer 615 546 1957
Mr. James Patrick Mackin Chairman, President & Chief Executive Officer 2 374 475 1967
Mr. Lance A. Berry CPA Executive Vice President of Finance, Chief Operating Officer & Chief Financial Officer 138 356 1972
Mr. Florian Tyrs Vice President of Global Operations 0 0
Dr. Robert C. Thomson Vice President of Research & Development 0 1970
Mr. Matthew A. Getz Vice President of Human Resources & Chief Human Resources Officer 0 1969
Lista ETF z ekspozycją na akcje Artivion, Inc.
Symbol ETF Ilość akcji Wartość
IJR 2 326 343 70 464 921
IWM 991 469 30 031 595
IJT 342 117 10 362 716
SPSM 318 791 9 795 672
IWO 276 740 8 382 443
XSMO 210 448 6 464 962
IHI 203 408 6 161 233
VTWO 200 783 5 939 161
SLYG 189 920 5 820 744
SCHA 182 089 5 593 774
VIOO 127 644 3 775 709
DFAS 119 209 3 662 100
VHT 113 354 3 353 011
DFAC 88 804 2 728 058
XHE 87 618 2 747 493
IWC 86 393 2 616 852
DWAS 78 453 2 410 076
IWN 64 103 1 941 688
ITOT 63 521 1 924 055
FYC 62 032 1 878 949
IDP6.L 57 469 1 740 748
IUS3.DE 57 469 1 740 748
ISP6.L 57 469 1 740 748
PTH 49 074 1 507 553
VIOG 48 403 1 189 745
FYX 45 664 1 383 162
CUS1.L 38 702 1 172 275
CUSS.L 38 702 1 172 275
CSUSS.MI 38 702 1 172 275
SXRG.DE 38 702 1 172 275
PSCH 38 632 1 186 775
PRFZ 32 769 1 006 663
ESML 32 426 996 126
VFMO 26 848 659 923
VTWG 26 422 781 562
WSML.L 25 775 780 718
IUSN.DE 25 775 780 718
WLDS.L 25 775 780 718
PSC 23 734 732 193
RSSL 20 773 667 851
GSSC 15 808 485 621
RZG 15 752 483 901
FHLC 15 371 474 195
RWJ 14 743 452 904
IJR.AX 13 448 625 329
IWV 10 623 321 761
DFUS 9 650 296 448
FAD 9 313 282 090
WSCR.L 9 191 282 355
SMLV 8 185 252 957
XSU.TO 6 925 286 215
DFAU 6 840 210 124
SPTM 6 759 204 739
VTWV 6 459 191 057
QVMS 6 241 191 723
ISCG 5 779 175 042
UMDV.AS 5 370 162 662
OMFS 3 965 121 804
UWM 3 858 118 517
URTY 3 203 98 396
VMO.TO 3 176 112 356
VTHR 3 174 93 886
XJR 3 014 92 590
ISCV 2 964 89 794
DCOR 2 942 90 378
AVSC 2 402 73 789
XEQT.TO 2 327 96 164
FLQS 2 116 65 828
DFUV 2 000 61 440
XUU.TO 1 892 83 304
ISCB 1 721 52 131
XSMC.TO 1 368 56 537
XSMH.TO 1 299 53 687
XAW.TO 1 281 52 923
SAA 697 21 411
XBAL.TO 359 15 814
ESIX 292 8 951
XUH.TO 270 8 178
VLU 189 5 746
MMTM 115 3 479
HDG 48 1 474
XTR.TO 11 342
USUE.DE 0 0
PZW.TO 0 0
USFM.L 0 0
Wiadomości dla Artivion, Inc.
Tytuł Treść Źródło Aktualizacja Link
Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock ATLANTA , May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning on May 15, 2025 (the "Shares"). prnewswire.com 2025-05-14 20:01:00 Czytaj oryginał (ang.)
Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript Artivion, Inc. (NYSE:AORT ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants John McAulay - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion's First Quarter 2025 Financial Conference Call. seekingalpha.com 2025-05-06 02:37:09 Czytaj oryginał (ang.)
Artivion (AORT) Lags Q1 Earnings Estimates Artivion (AORT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.06 per share a year ago. zacks.com 2025-05-05 22:51:20 Czytaj oryginał (ang.)
Artivion Reports First Quarter 2025 Financial Results First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basis Net loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025 Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 2024 30-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference performance goal Submitted the clinical module of the pre-market approval application (PMA) to the FDA for the AMDS Hybrid Prosthesis ATLANTA , May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2025. "I am pleased with our first quarter results as we returned to normal operations following our previously disclosed cybersecurity incident while making substantial progress on our strategic growth initiatives. prnewswire.com 2025-05-05 20:05:00 Czytaj oryginał (ang.)
Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting 30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA , May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS. prnewswire.com 2025-05-05 11:00:00 Czytaj oryginał (ang.)
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results ATLANTA , April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. prnewswire.com 2025-04-21 20:10:00 Czytaj oryginał (ang.)
Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength? Artivion (AORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2025-04-10 14:11:19 Czytaj oryginał (ang.)
Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference ATLANTA , March 4, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. prnewswire.com 2025-03-04 18:05:00 Czytaj oryginał (ang.)
Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com 2025-02-27 12:35:40 Czytaj oryginał (ang.)
Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript Artivion, Inc. (NYSE:AORT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Fourth Quarter and Year End 2024 Financial Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. seekingalpha.com 2025-02-25 01:00:16 Czytaj oryginał (ang.)
Artivion (AORT) Reports Break-Even Earnings for Q4 Artivion (AORT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.12. This compares to earnings of $0.11 per share a year ago. zacks.com 2025-02-24 20:21:34 Czytaj oryginał (ang.)
Artivion Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basis Achieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal year Adjusted EBITDA increased 15% to $17.6 million in the fourth quarter of 2024 compared to $15.3 million in the fourth quarter of 2023. prnewswire.com 2025-02-24 18:05:00 Czytaj oryginał (ang.)
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results ATLANTA , Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 financial results will be released on Monday, February 24, 2025 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. prnewswire.com 2025-02-10 18:10:00 Czytaj oryginał (ang.)
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks. None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth. investors.com 2025-02-03 17:09:34 Czytaj oryginał (ang.)
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA , Jan. 27, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation. prnewswire.com 2025-01-27 10:00:00 Czytaj oryginał (ang.)
Best Momentum Stocks to Buy for January 7th NN, VERX and AORT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 7, 2024. zacks.com 2025-01-07 13:25:40 Czytaj oryginał (ang.)
New Strong Buy Stocks for January 7th AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024. zacks.com 2025-01-07 10:21:11 Czytaj oryginał (ang.)
US medical device giant Artivion says hackers stole files during cybersecurity incident Artivion, a medical device company that manufactures implantable tissues for cardiac and vascular transplant applications, says its services have been “disrupted” due to a cybersecurity incident. techcrunch.com 2024-12-09 12:52:32 Czytaj oryginał (ang.)
Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis ATLANTA , Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections. prnewswire.com 2024-12-09 10:00:00 Czytaj oryginał (ang.)
Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript Artivion, Inc. (NYSE:AORT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Daniel Stauder - JMP Securities Suraj Kalia - Oppenheimer Nelson Cox - Lake Street Capital Mike Matson - Needham & Company Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Third Quarter 2024 Financial Conference Call. At this time, all participants are in listen only mode. seekingalpha.com 2024-11-09 14:02:09 Czytaj oryginał (ang.)
Artivion (AORT) Tops Q3 Earnings and Revenue Estimates Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago. zacks.com 2024-11-07 21:10:54 Czytaj oryginał (ang.)
Artivion Reports Third Quarter 2024 Financial Results Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis Net loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024 Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023 Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug Administration Enrollment completed in NEXUS TRIOMPHE clinical trial Received regulatory approval from the National Medical Products Administration (NMPA) to commercialize BioGlue Surgical Adhesive in China. Commercialization expected in the second half of 2025. prnewswire.com 2024-11-07 18:05:00 Czytaj oryginał (ang.)
Artivion to Participate in Upcoming Investor Conferences ATLANTA , Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at the Lotte New York Palace. prnewswire.com 2024-11-05 18:15:00 Czytaj oryginał (ang.)
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results ATLANTA , Oct. 24, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results will be released on Thursday, November 7, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. prnewswire.com 2024-10-24 20:15:00 Czytaj oryginał (ang.)
Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting 5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfusion Resolution in 90% of Affected Subjects Post-AMDS Implantation 1-Year Data from the NEOS Study Indicate E-vita Open Neo is Safe and Effective in the Treatment of Aortic Arch Pathologies with Low Combined Major Adverse Events Rate ATLANTA , Oct. 10, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS DARTS and PERSEVERE trials and E-vita Open Neo study presented in Late-Breaking Science presentations at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon, Portugal. The presentation regarding the AMDS DARTS trial highlighted 5-year aortic remodeling data that demonstrate positive, durable patient outcomes following AMDS implantation. prnewswire.com 2024-10-10 20:10:00 Czytaj oryginał (ang.)
Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript Artivion, Inc. (NYSE:AORT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Suraj Kalia - Oppenheimer John McAulay - Stifel Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. And welcome to Artivion's Second Quarter 2024 Financial Conference Call. seekingalpha.com 2024-08-10 18:45:26 Czytaj oryginał (ang.)
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates Artivion (AORT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago. zacks.com 2024-08-08 22:50:51 Czytaj oryginał (ang.)
Artivion Reports Second Quarter 2024 Financial Results Second Quarter Highlights:  Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency basis Net loss was ($2.1) million or ($0.05) per fully diluted share and non-GAAP net income was $2.9 million or $0.07 per fully diluted share in the second quarter of 2024 Adjusted EBITDA increased 35% to $18.6 million in the second quarter of 2024 compared to $13.8 million in the second quarter of 2023 Raised FY24 revenue guidance to 10% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint Raised FY24 adjusted EBITDA guidance to 28% to 34% year-over-year growth, an increase of 1% at the midpoint ATLANTA , Aug. 8, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2024. "In the second quarter, we continued to make substantial progress on our strategic growth initiatives to drive sustained and profitable growth, and we further solidified our position as the leader in the aortic disease space. prnewswire.com 2024-08-08 20:05:00 Czytaj oryginał (ang.)
Artivion to Participate in Upcoming Investor Conferences ATLANTA , Aug. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at the InterContinental Boston Hotel. prnewswire.com 2024-08-05 20:10:00 Czytaj oryginał (ang.)
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. prnewswire.com 2024-07-25 20:10:00 Czytaj oryginał (ang.)
3 Earnings All-Stars With More Room to Run Earnings are essential to determining which stocks will outperform. Unsurprisingly, earnings outperformers also see strong price appreciation. investorplace.com 2024-07-03 12:00:00 Czytaj oryginał (ang.)
Artivion Amends Agreements with Endospan Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated  ATLANTA , July 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced it has amended its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer of the NEXUS® Stent Graft System ("NEXUS"). prnewswire.com 2024-07-01 20:05:00 Czytaj oryginał (ang.)
Data-Driven Growth Fuels More Upside For Overlooked Artivion Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval trial data for the On-X aortic valve and a successful PERSEVERE IDE study for AMDS hybrid prosthesis can drive additional revenue growth. A strong pipeline, including NEXUS and ARCEVO stent graft systems, can support a longer runway of continued revenue growth. seekingalpha.com 2024-06-21 21:01:54 Czytaj oryginał (ang.)
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue? Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2024-05-08 14:17:14 Czytaj oryginał (ang.)
Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript Artivion, Inc. (NYSE:AORT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Suraj Kalia - Oppenheimer & Company Frank Takkinen - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion First Quarter 2024 Financial Conference Call. seekingalpha.com 2024-05-07 02:47:07 Czytaj oryginał (ang.)
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago. zacks.com 2024-05-06 22:21:04 Czytaj oryginał (ang.)
Artivion Reports First Quarter 2024 Financial Results First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $7.5 million or $0.18 per fully diluted share and non-GAAP net income was $2.6 million or $0.06 per fully diluted share in the first quarter of 2024 Non-GAAP adjusted EBITDA increased 60% to $17.3 million in the first quarter of 2024 compared to $10.8 million in the first quarter of 2023 Revised FY24 revenue guidance to 9% to 12% year-over-year growth on a constant currency basis, an increase of 0.5% at the midpoint ATLANTA , May 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2024. "We are very pleased with our first quarter results as we maintained growth momentum and executed on key operational priorities. prnewswire.com 2024-05-06 20:05:00 Czytaj oryginał (ang.)